HLA-A*2402-restricted peptide vaccine / Shiga University - LARVOL DELTA

Cancer peptide vaccine to suppress postoperative recurrence in esophageal SCC patients with induction of antigen-specific CD8+ T cell. (ASCO 2017) - "...One mg each of three peptides mixed with Montanide was injected to patients with HLA-A*2402 20 times in a 6-months period... Our cancer peptide vaccines induced the antigen-specific CD8+ T cell highly and efficiently, and suppressed recurrence with the strong immune responses."

Clinical • Biosimilar • Esophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Solid Tumor

A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric Cancer. (PubMed, Yonago Acta Med) - "The vaccine therapy combined with S-1 was manageable and safe adjuvant therapy for stage III gastric cancer. Furthermore, the optimal relative dose intensity of S-1 was achieved in combination group, although the injection-site reaction should be considered."

Journal • Biosimilar • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor